NVIDIA rolls out new tool for medical device makers

Date:

Share:

Silicon Valley giant NVIDIA is expanding its arsenal of products for healthcare with the launch of Clara Holoscan MGX, a tool designed to help medical device organizations develop artificial intelligence tools. The company said the new technology was created to help industry players meet regulatory standards.

“Deploying real-time AI in healthcare and life sciences is critical to enable the next frontiers in surgery, diagnostics and drug discovery,” said Kimberly Powell, vice president of healthcare at NVIDIA.

“Clara Holoscan MGX, with its unique combination of AI, accelerated computing and advanced visualization, accelerates the productization of AI and provides software-as-a-service business models for the medical device industry.”

The platform builds on its previously launched product, the Clara Holoscan, which developed to give industry stakeholders a computational infrastructure to stream data from medical devices. The company said that Clara Holoscan MGX can process “high-throughput data streams for real-time insights.”

WHY IT MATTERS 

Medical devices are becoming increasingly connected and AI-backed. NVIDIA is pitching this new tool as a way to help cut down on time to market for “software-defined medical devices.”  

The new tool can be used in a variety of ways, including medical device development through commercialization, according to NVIDIA’s web page.

THE LARGER TREND 

NVIDIA has a number of initiatives in the healthcare space. In 2021 the company announced that it had teamed up with pharma company AstraZeneca and the University of Florida on an AI for drug discovery and patient care initiative. NVIDIA has also joined forces with Harvard University on an AI-based tool kit to help researchers gain access and insights about DNA.

During the COVID-19 pandemic the company released an automated speech recognition and natural language processing technology that can transcribe and organize information from a telemedicine visit for patients and clinicians.

 

━ more like this

23andMe posts $217M net loss during ‘transitional’ fiscal year

23andMe reported a $217 million net loss during its fiscal year 2022, which ended March 31, compared with $184 million during the prior year.  The...

Study: VR therapeutic reduces pain intensity long term, compared with sham app

A virtual reality therapeutic program reduces pain intensity up to six months later, compared with a sham app, according to a study published in...

Roundup: Telehealth platform for endometriosis launched in Malaysia, India upgrades health ID app, and more briefs

Bayer launches telehealth platform for endometriosis in Malaysia Pharmaceutical firm Bayer has partnered with digital health company DoctorOnCall and the Endometriosis Association of Malaysia (MyEndosis)...

Clinical trial tech company uMotif scores $22.5M to continue international expansion

Patient data capture and clinical trial tech company uMotif announced Wednesday it had secured $25.5 million from a fund managed by Athyrium Capital Management. The...

Transcarent hires chief marketing officer from Fitbit and more digital health hires

Transcarent, a healthcare platform focused on self-insured employers, has appointed Tim Rosa as chief marketing officer. Rosa comes to Transcarent from health-tracking wearable maker Fitbit,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here